OXAPROZIN

Post-LOE

Teva

ANDAORALTABLET

Approved

Jul 2002

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

3/8 — Basic

OXAPROZIN by Teva is analgesic, anti-inflammatory, and antipyretic properties. First approved in 2002.

Drug data last refreshed 18h ago

Mechanism of Action

analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of oxaprozin, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Oxaprozin is a potent inhibitor of prostaglandin synthesis in vitro. Oxaprozin…

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (1)

NCT03350386Phase 1Completed

Drug-drug Interaction Study of FYU-981 and Oxaprozin

Started Nov 2017

12 enrolled

Healthy

Company

Worked on OXAPROZIN at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.